[go: up one dir, main page]

AR066476A1 - Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos - Google Patents

Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos

Info

Publication number
AR066476A1
AR066476A1 ARP080101935A ARP080101935A AR066476A1 AR 066476 A1 AR066476 A1 AR 066476A1 AR P080101935 A ARP080101935 A AR P080101935A AR P080101935 A ARP080101935 A AR P080101935A AR 066476 A1 AR066476 A1 AR 066476A1
Authority
AR
Argentina
Prior art keywords
cysteine
designed
antibodies
muc16
conjugaods
Prior art date
Application number
ARP080101935A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR066476A1 publication Critical patent/AR066476A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los anticuerpos anti-MUC16 disenados con cisteína se disenaron sustituyendo uno o más aminoácidos de un anticuerpo anti-MUC16, original por aminoácidos de cisteína reactivos sin enlace cruzado. Se proporcionan los métodos de diseno, preparacion,cribado y seleccion de los anticuerpos anti-MUC16 disenados con cisteína. Los anticuerpos (Ab) anti-MUC16 disenados con cisteína se conjugan con una o más porciones de fármaco (D) a través de un enlazador (L) para formar conjugados de fármaco yanticuerpo anti-MUC16 disenado con cisteína que tienen la formula 1: Ab-(L-D)p donde p es un numero situado entre 1 y 4. Se describen los usos diagnosticos y terapéuticos de los compuestos y composiciones de fármaco y anticuerpo disenado concisteína.
ARP080101935A 2007-05-08 2008-05-07 Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos AR066476A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91665707P 2007-05-08 2007-05-08

Publications (1)

Publication Number Publication Date
AR066476A1 true AR066476A1 (es) 2009-08-19

Family

ID=39789637

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101935A AR066476A1 (es) 2007-05-08 2008-05-07 Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos

Country Status (11)

Country Link
US (2) US7723485B2 (es)
EP (1) EP2144628B1 (es)
JP (1) JP5290276B2 (es)
CN (1) CN101687037B (es)
AR (1) AR066476A1 (es)
AU (1) AU2008251608B2 (es)
CA (1) CA2683568A1 (es)
CL (1) CL2008001334A1 (es)
PE (1) PE20090245A1 (es)
TW (1) TW200902554A (es)
WO (1) WO2008141044A2 (es)

Families Citing this family (256)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
USRE47223E1 (en) * 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AR066476A1 (es) 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
MY188455A (en) * 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
KR101667062B1 (ko) 2008-07-15 2016-10-17 제넨테크, 인크. 안트라시클린 유도체 접합체, 그의 제조 방법 및 항-종양 화합물로서의 그의 용도
WO2010065044A1 (en) * 2008-12-05 2010-06-10 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Blocking mesothelin peptide fragments
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
ES2547712T3 (es) 2009-02-27 2015-10-08 Genentech, Inc. Métodos y composiciones para el marcado de proteínas
TWI502068B (zh) 2009-07-15 2015-10-01 Aimm Therapiutics B V 革蘭氏陽性菌特異性結合的化合物
PT2552959T (pt) 2010-03-26 2017-04-21 Memorial Sloan Kettering Cancer Center Anticorpos para muc16 e métodos de utilização dos mesmos
EP2554669B1 (en) * 2010-03-26 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Novel antibody having modification site introduced therein, and antibody fragment
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
EP2579897A1 (en) 2010-06-08 2013-04-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
UA115641C2 (uk) 2010-12-20 2017-11-27 Дженентек, Інк. Виділене антитіло, яке зв'язує мезотелін, та імунокон'югат, що його містить
BR112013017980A2 (pt) 2011-01-14 2017-06-27 Redwood Bioscience Inc polipeptídeos de imunoglobulina marcado com aldeído e método de uso dos mesmos
PL2675479T3 (pl) 2011-02-15 2016-09-30 Cytotoksyczne pochodne benzodiazepiny
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
SG11201401406YA (en) 2011-10-14 2014-05-29 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
KR102049803B1 (ko) * 2011-10-27 2019-11-29 젠맵 에이/에스 이종이량체 단백질의 생산
NZ756727A (en) 2011-10-28 2022-12-23 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
EP2794653B1 (en) 2011-12-23 2019-03-13 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US20150011736A1 (en) 2012-01-20 2015-01-08 Sea Lane Biotechnologies, Llc Binding molecule conjugates
BR112014020697B1 (pt) 2012-02-24 2024-01-09 Alteogen Inc Anticorpo modificado compreendendo um motivo contendo cisteína na terminação do anticorpo, conjugado anticorpo-droga modificado compreendendo uma droga ligada ao anticorpo modificado e método de produção do mesmo
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP2906251B1 (en) 2012-10-12 2017-09-27 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
CA2941485C (en) 2012-10-12 2018-06-12 Philip Wilson Howard Pyrrolobenzodiazepines and conjugates thereof
CA3060520C (en) 2012-10-12 2022-05-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
TR201808051T4 (tr) 2012-10-12 2018-06-21 Adc Therapeutics Sa Pirrolobenzodiazepin antikor konjugatları.
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
JP6392763B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
CA2885305C (en) 2012-10-12 2019-11-12 Spirogen Sarl Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
US9393327B2 (en) 2012-12-19 2016-07-19 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
EA031585B1 (ru) 2012-12-21 2019-01-31 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
WO2014096365A1 (en) 2012-12-21 2014-06-26 Spirogen Sàrl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CN103933575B (zh) 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
ES2874493T3 (es) * 2013-02-08 2021-11-05 Novartis Ag Sitios específicos para modificar anticuerpos para generar inmunoconjugados
RU2019109456A (ru) 2013-02-22 2019-04-10 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые конъюгаты антител и их применения
HK1219423A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
TWI636063B (zh) 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
IL289918B2 (en) 2013-03-11 2025-07-01 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
MX364330B (es) 2013-03-13 2019-04-23 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
KR102057755B1 (ko) 2013-03-13 2019-12-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
ES2996807T3 (en) 2013-03-15 2025-02-13 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
JP6286532B2 (ja) 2013-04-29 2018-02-28 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
PL3004162T3 (pl) 2013-05-31 2020-07-27 Genentech, Inc. Przeciwciała i koniugaty przeciwko kwasowi tejchojowemu ściany komórkowej
MX369758B (es) 2013-05-31 2019-11-20 Genentech Inc Anticuerpos anti-acido teicoico de pared y conjugados.
CN110251683A (zh) * 2013-06-24 2019-09-20 Abl生物公司 具有改进的稳定性的抗体-药物缀合物及其用途
KR101899306B1 (ko) 2013-07-03 2018-10-04 서울대학교산학협력단 시스테인으로 변형된 닭의 항체 및 이를 이용한 부위-특이적 접합
CN105358985B (zh) * 2013-07-09 2018-08-28 内布拉斯加大学董事会 靶向糖蛋白以治疗癌症的新方法
CN105636612B (zh) 2013-08-12 2020-01-14 基因泰克公司 抗体-药物缀合物及使用和治疗方法
WO2015031396A1 (en) 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
RU2016111131A (ru) 2013-08-28 2017-10-03 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Способы конъюгации сайт-специфических антител и композиции
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10053511B2 (en) 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
RS62157B1 (sr) * 2013-11-19 2021-08-31 Remegen Co Ltd Anti-her2 antitelo i njegov konjugat
EP3080607A4 (en) 2013-12-12 2017-07-12 AbbVie Stemcentrx LLC Novel anti-dpep3 antibodies and methods of use
CN105828840B (zh) 2013-12-16 2020-08-04 基因泰克公司 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法
RU2689388C1 (ru) 2013-12-16 2019-05-28 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
AU2015218633A1 (en) 2014-02-21 2016-09-01 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
CN104788566A (zh) * 2014-03-11 2015-07-22 南京任诺药业有限公司 用于构建放射性同位素偶联标记的ADC药物的改造抗体IgG1-CH-V280C
CN104672330A (zh) * 2014-03-11 2015-06-03 南京任诺药业有限公司 用于构建放射性同位素偶联标记的ADC药物的改造抗体IgG1-CH-N267C
ES3051373T3 (en) 2014-03-19 2025-12-26 Genzyme Corp Site-specific glycoengineering of targeting moieties
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
PT3134125T (pt) 2014-04-25 2020-01-13 Pf Medicament Conjugado-fármaco-anticorpo e sua utilização para o tratamento de cancro
KR102357032B1 (ko) 2014-04-25 2022-02-08 피에르 파브르 메디카먼트 Igf-1r 항체 및 암 치료를 위한 운반체를 어드레싱하는 그의 용도
LT3134124T (lt) 2014-04-25 2019-05-27 Pierre Fabre Médicament Igf-1r antikūno ir vaisto konjugatas, ir jo panaudojimas vėžio gydymui
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
RU2021106673A (ru) 2014-07-24 2021-11-25 Дженентек, Инк. Способы конъюгации агента с тиольным компонентом в белке, который содержит по меньшей мере одну трисульфидную связь
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CN106714844B (zh) 2014-09-12 2022-08-05 基因泰克公司 蒽环类二硫化物中间体、抗体-药物缀合物和方法
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2016044396A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
MX2017003523A (es) 2014-09-17 2017-11-08 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas.
EP3799887A1 (en) 2014-10-09 2021-04-07 Genzyme Corporation Glycoengineered antibody drug conjugates
KR20170058432A (ko) 2014-10-10 2017-05-26 화이자 인코포레이티드 상승 효과적 아우리스타틴 조합
EP3212216A4 (en) 2014-10-29 2018-04-18 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha2b variants
MX379396B (es) 2014-11-25 2025-03-11 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepina y anticuerpo.
BR112017011325A2 (pt) * 2014-12-03 2020-07-21 Genentech, Inc. ?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?
JP6752204B2 (ja) 2014-12-03 2020-09-09 ジェネンテック， インコーポレイテッド 四級アミン化合物及びその抗体−薬物コンジュゲート
HK1244230A1 (zh) * 2014-12-03 2018-08-03 F. Hoffmann-La Roche Ag 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
AU2015360613A1 (en) * 2014-12-09 2017-06-29 Abbvie Inc. Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
WO2016094517A1 (en) * 2014-12-09 2016-06-16 Abbvie Inc. Bcl-xl inhibitory compounds and antibody drug conjugates including the same
ES2772348T3 (es) * 2014-12-19 2020-07-07 Ablynx Nv Dímeros de Nanobody con uniones cisteína
EP3259285A2 (en) 2015-02-16 2017-12-27 Lonza Ltd Cl and/or ch1 mutated antibodies for drug conjugation
CA2979976A1 (en) 2015-03-17 2016-09-22 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
BR112017020149A8 (pt) 2015-03-27 2023-05-02 Regeneron Pharma Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
WO2016164916A1 (en) 2015-04-10 2016-10-13 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
WO2016205176A1 (en) * 2015-06-15 2016-12-22 Genentech, Inc. Antibodies and immunoconjugates
EP4678240A2 (en) 2015-07-12 2026-01-14 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
US9669106B2 (en) 2015-10-26 2017-06-06 Pierre Fabre Medicament Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer
US10858423B2 (en) 2015-10-26 2020-12-08 Pierre Fabre Medicament Composition for the treatment of IGF-1R expressing cancer
EA201891482A1 (ru) 2015-12-21 2018-12-28 Бристол-Маерс Сквибб Компани Модифицированные антитела для сайт-специфической конъюгации
CN108712911A (zh) * 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
WO2017132173A1 (en) 2016-01-25 2017-08-03 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3413910A1 (en) * 2016-02-12 2018-12-19 Janssen Pharmaceutica NV Anti-vista (b7h5) antibodies
CN108713020A (zh) 2016-03-04 2018-10-26 豪夫迈·罗氏有限公司 制备抗体-利福霉素缀合物的方法
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
WO2017176648A1 (en) 2016-04-04 2017-10-12 Rutgers, The State University Of New Jersey Topoisomerase poisons
KR20180135458A (ko) 2016-04-26 2018-12-20 알.피.쉐러 테크놀러지즈 엘엘씨 항체 컨쥬게이트 및 이의 제조 및 이용 방법
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
CN109476648B (zh) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 司维司群抗体-药物缀合物和使用方法
WO2018009811A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
CA3030926A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd47 combination therapy
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
CN119119244A (zh) * 2016-08-16 2024-12-13 里珍纳龙药品有限公司 用于对混合物中的个体抗体进行量化的方法
SMT202200359T1 (it) 2016-09-23 2022-11-18 Regeneron Pharma Anticorpi anti-muc16 (mucina 16)
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
CN107789630A (zh) * 2016-10-08 2018-03-13 四川百利药业有限责任公司 半胱氨酸改造的抗体‑毒素偶联物及其制备方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
MX2019005583A (es) 2016-11-14 2019-10-21 Hangzhou Dac Biotech Co Ltd Vinculantes de conjugacion, conjugados de molecula de union a celulas que contienen los vinculantes, metodos de creacion y usos de dichos conjugados con los vinculantes.
JP7105235B2 (ja) 2016-12-01 2022-07-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔイメージングのための放射性標識された抗ｐｄ－ｌ１抗体
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
RS62343B1 (sr) 2017-02-08 2021-10-29 Adc Therapeutics Sa Pirolobenzodiazepin-antitelo konjugati
WO2018146189A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2018146585A1 (en) 2017-02-08 2018-08-16 Pfizer Inc. Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS63502B1 (sr) 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US11613573B2 (en) 2017-04-26 2023-03-28 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
EP3624854A1 (en) 2017-05-16 2020-03-25 Université de Strasbourg Protein-drug conjugates and their use in the treatment of cancers
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
US20210100912A1 (en) * 2017-06-19 2021-04-08 Sichuan Baili Pharmaceutical Co. Ltd. Antibody-drug conjugate having acidic self-stabilization junction
EP3770170A4 (en) * 2017-06-20 2021-12-22 Sichuan Baili Pharm Co. Ltd SITE SCREENING OF FIXED-POINT COUPLING OF A CYSTEINE-MODIFIED ANTIBODY-TOXIN CONJUGATE (TDC)
SI3661562T1 (sl) * 2017-08-04 2025-01-31 Amgen Inc. Postopek konjugiranja CYS-MABS
HRP20220311T1 (hr) 2017-08-18 2022-05-13 Medimmune Limited Konjugati pirolobenzodiazepina
CN107583058B (zh) * 2017-09-20 2020-09-18 厉保秋 一种t-2毒素-抗体缀合物及其用途
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
WO2019100005A1 (en) * 2017-11-18 2019-05-23 De Magalhaes Nzola Product and process for employing gc7 (n1-guanyl-1,7-diaminoheptane) based antigen binding conjugates in cancer therapy
CN110133271B (zh) * 2018-02-09 2022-12-13 北京豪迈生物工程股份有限公司 一种将抗体或其抗原结合片段共价结合至颗粒表面的方法
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN108727498B (zh) * 2018-04-24 2021-11-26 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
CN108714220B (zh) * 2018-04-24 2021-11-19 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
CN108727499B (zh) * 2018-04-24 2021-12-31 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
CN108743966B (zh) * 2018-04-24 2021-10-19 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
US11319380B2 (en) 2018-06-04 2022-05-03 Precigen, Inc. MUC16 specific chimeric antigen receptors and uses thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP4342543A3 (en) 2018-09-11 2024-06-19 F. Hoffmann-La Roche AG Tert-butyl (s)-2-(4-(phenyl)-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain brd4 inhibitors for treating cancer
EP3866856A1 (en) 2018-10-19 2021-08-25 MedImmune Limited Pyrrolobenzodiazepine conjugates
CA3112977A1 (en) 2018-10-19 2020-04-23 Medimmune Limited Pyrrolobenzodiazepine conjugates
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
CN119896730A (zh) 2018-12-17 2025-04-29 雷维托普有限公司 双免疫细胞衔接物
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
TWI756633B (zh) 2019-02-15 2022-03-01 大陸商上海藥明生物技術有限公司 具有改善的同質性的抗體－藥物綴合物、其藥物組合物、用途和製備方法
EP3938372B1 (en) 2019-03-15 2023-10-25 MedImmune Limited Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
LT3946464T (lt) 2019-03-29 2022-11-10 Medimmune Limited Junginiai ir jų konjugatai
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
CN111825742B (zh) * 2019-04-18 2024-01-30 陈铭 Ctpa作为特种偶合剂用于氨基酸离子液体的多肽固相合成
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP2022537158A (ja) 2019-06-13 2022-08-24 ボルト バイオセラピューティクス、インコーポレーテッド アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用
KR20220029725A (ko) 2019-06-29 2022-03-08 항저우 디에이씨 바이오테크 씨오, 엘티디 세포-결합 분자-튜불리신 유도체 접합체 및 이의 제조 방법
WO2021046112A1 (en) 2019-09-03 2021-03-11 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
US20220347310A1 (en) 2019-09-30 2022-11-03 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022007719A2 (pt) 2019-10-25 2022-07-12 Bolt Biotherapeutics Inc Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado
WO2021080608A1 (en) 2019-10-25 2021-04-29 Medimmune, Llc Branched moiety for use in conjugates
CN110922476A (zh) * 2019-12-16 2020-03-27 蓝怡科技集团股份有限公司 一种生物素偶联抗体及其制备方法和应用
BR112022014391A2 (pt) 2020-01-22 2022-09-13 Medimmune Ltd Compostos e conjugados dos mesmos
TW202140076A (zh) 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
WO2021226440A1 (en) 2020-05-08 2021-11-11 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
AU2021326516A1 (en) 2020-08-13 2023-04-13 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
US20230331867A1 (en) 2020-09-04 2023-10-19 Novarock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
IL301041A (en) 2020-09-11 2023-05-01 Medimmune Ltd Therapeutic B7-H4 binding molecules
US20240042050A1 (en) 2020-12-11 2024-02-08 Bolt Biotherapeutics, Inc. Anti-her2 immunoconjugates, and uses thereof
CA3200168A1 (en) 2020-12-11 2022-06-16 Shelley Erin ACKERMAN Anti-pd-l1 immunoconjugates, and uses thereof
US20240091370A1 (en) 2020-12-11 2024-03-21 Bolt Biotherapeutics, Inc. Anti-her2 immunoconjugates, and uses thereof
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
EP4259210A2 (en) 2020-12-11 2023-10-18 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
EP4046996A1 (en) 2021-02-19 2022-08-24 Universität Bielefeld Cryptophycin compounds and conjugates thereof
CN114957476A (zh) * 2021-02-23 2022-08-30 复旦大学 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
EP4313161A1 (en) 2021-03-26 2024-02-07 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
CA3212926A1 (en) 2021-03-26 2022-09-29 Gary Brandt 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
GB202105187D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CA3235132A1 (en) * 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
WO2023076599A1 (en) 2021-10-29 2023-05-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합
EP4429765A1 (en) 2021-11-10 2024-09-18 Astrazeneca AB Antibody molecules and conjugates
WO2023088963A1 (en) 2021-11-19 2023-05-25 Adc Therapeutics Sa Anti-il-13ralpha2 conjugates
WO2023088966A1 (en) 2021-11-19 2023-05-25 Adc Therapeutics Sa Anti-psma conjugates
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
EP4230222A1 (en) 2022-02-17 2023-08-23 Oxsonics Limited Combination therapy with an anti-axl antibody-pbd conjugate and nanocups
WO2023160982A1 (en) 2022-02-28 2023-08-31 Adc Therapeutics Sa Dosage regimen
EP4489859A1 (en) 2022-03-09 2025-01-15 Astrazeneca AB Binding molecules against fr alpha
WO2023170216A1 (en) 2022-03-11 2023-09-14 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
CA3259492A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
EP4583979A1 (en) 2022-09-09 2025-07-16 MyricX Pharma Limited Cytotoxic imidazo[1,2-a]pyridine compounds and their use in therapy
EP4611897A1 (en) 2022-11-01 2025-09-10 Heidelberg Pharma Research GmbH Anti-gucy2c antibody and uses thereof
WO2024129756A1 (en) * 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
EP4633738A1 (en) 2022-12-14 2025-10-22 Pheon Therapeutics Ltd Cytotoxic compounds
WO2024137619A1 (en) 2022-12-20 2024-06-27 Bolt Biotherapeutics, Inc. Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
JP2026502860A (ja) 2022-12-23 2026-01-27 ジェネンテック， インコーポレイテッド セレブロン分解剤コンジュゲートおよびその使用
EP4410314A1 (en) 2023-02-02 2024-08-07 ADC Therapeutics SA Combination therapy comprising anti-cd22 antibody-drug conjugate and irak1 inhibitor
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
EP4665399A1 (en) 2023-02-16 2025-12-24 Astrazeneca AB Combination therapies for treatment of cancer with therapeutic binding molecules
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
EP4680285A1 (en) 2023-03-13 2026-01-21 Heidelberg Pharma Research GmbH Subcutaneously administered antibody-drug conjugates for use in cancer treatment
WO2024223899A1 (en) 2023-04-28 2024-10-31 Medimmune Limited B7-h4 therapeutic binding molecules for the treatment of cancer
WO2025083067A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-claudin-6 conjugates
WO2025083064A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-asct2 conjugates
WO2025083061A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-napi2b conjugates
EP4548936A1 (en) 2023-10-30 2025-05-07 BioNTech SE Antibody-drug conjugates having a tailor-made drug-to-antibody ratio
WO2025109097A2 (en) 2023-11-24 2025-05-30 Heidelberg Pharma Research Gmbh Novel nicotinamide phosphoribosyltransferase inhibitors and uses thereof
EP4566631A1 (en) 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof
US20250186604A1 (en) 2023-12-06 2025-06-12 Adc Therapeutics Sa Anti-psma antibody conjugates
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
EP4596569A1 (en) * 2024-02-05 2025-08-06 Syndivia Site specific antibody drug conjugates and their process of preparation
GB202403391D0 (en) 2024-03-08 2024-04-24 Myricx Pharma Ltd Novel compounds and their use in therapy
GB202405758D0 (en) 2024-04-24 2024-06-05 King S College London Compounds
GB202407700D0 (en) 2024-05-30 2024-07-17 Francis Crick Institute Ltd F-actin binding agents
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof
WO2026020031A2 (en) 2024-07-18 2026-01-22 Novarock Biotherapeutics, Ltd. Cdh17 antibodies and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1995009864A1 (en) 1993-10-01 1995-04-13 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivative
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6858710B2 (en) 1998-12-17 2005-02-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2002344326A1 (en) 2001-05-11 2002-11-25 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, ca125, and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
AU2002363939A1 (en) 2001-11-20 2003-06-10 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
WO2003049704A2 (en) 2001-12-11 2003-06-19 University Of Massachusetts Antibodies to treat cancer
AU2002316365A1 (en) 2002-06-21 2004-01-06 Lewyn B. Boler Jr. Device and system for coating a surface
CA2491017A1 (en) 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
SI2357006T1 (sl) 2002-07-31 2016-01-29 Seattle Genetics, Inc. Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
LT2891666T (lt) 2002-10-16 2017-10-10 Purdue Pharma L.P. Antikūnai, kurie prisiriša su ląstelėmis susijusį ca 125/o722p ir jų naudojimo būdas
CA2505919A1 (en) 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Arkansas Ca125 gene and its use for diagnostic and therapeutic interventions
JP4532409B2 (ja) 2003-01-23 2010-08-25 小野薬品工業株式会社 ヒトｐｄ−１に対し特異性を有する物質
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
US20060122377A1 (en) 2004-02-19 2006-06-08 Genentech, Inc. CDR-repaired antibodies
EP1753463A2 (en) 2004-06-01 2007-02-21 Genentech, Inc. Antibody drug conjugates and methods
KR101364276B1 (ko) * 2004-09-03 2014-02-20 제넨테크, 인크. 인간화 항-베타７ 길항제 및 그의 용도
US7521541B2 (en) * 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
EP3505191A1 (en) * 2004-11-12 2019-07-03 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
US8404803B2 (en) 2005-03-31 2013-03-26 Chugai Seiyaku Kabushiki Kaisha Cancer-associated antigen analogue peptides and uses thereof
US7989595B2 (en) * 2005-06-20 2011-08-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
AR066476A1 (es) 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos

Also Published As

Publication number Publication date
CN101687037A (zh) 2010-03-31
AU2008251608B2 (en) 2014-03-27
TW200902554A (en) 2009-01-16
EP2144628B1 (en) 2012-10-17
JP5290276B2 (ja) 2013-09-18
US20080311134A1 (en) 2008-12-18
EP2144628A2 (en) 2010-01-20
WO2008141044A3 (en) 2008-12-31
PE20090245A1 (es) 2009-03-17
US7723485B2 (en) 2010-05-25
CA2683568A1 (en) 2008-11-20
WO2008141044A2 (en) 2008-11-20
USRE47194E1 (en) 2019-01-08
JP2010526821A (ja) 2010-08-05
AU2008251608A1 (en) 2008-11-20
CN101687037B (zh) 2013-07-10
CL2008001334A1 (es) 2008-09-22

Similar Documents

Publication Publication Date Title
AR066476A1 (es) Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
CO6390071A2 (es) Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo
CO6480930A2 (es) Composiciones y procedimientos para preparar composiciones inmunogénicas de conjugado de polisacárido capsular de serotipo 5 y 8 de staphylococcus aureus.
MX2021012492A (es) Agonistas de glp-1r y usos de los mismos.
CO2021014566A2 (es) Compuestos y conjugados de estos
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
MX340674B (es) Conjugados de anticuerpo de ingenieria de cisteina, radioetiquetados con circonio.
HN2008001103A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina
ECSP099403A (es) Formulacion parenteral del anticuerpo abeta
CR10273A (es) "anticuerpos anti-5t4 y usos de los mismos"
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
CR20150625A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
TR201906970T4 (tr) Fenilefrin ihtiva eden sıvı formülasyonlar.
EP2244729A4 (en) CYSTEIN-MANIPULATED ANTIBODIES FOR STATION-SPECIFIC CONJUGATION
CL2010001146A1 (es) Proteina recombinante de circovirus porcino tipo 2 (pcv2); uso de la proteina recombinante para prevenir una infección por pcv2; un envase que comprende la composición inmunogénica (div exp 3475-2005).
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
AR096015A1 (es) Conjugados de fármacos con anticuerpos
ECSP12011964A (es) Anticuerpos de unión al dominio extracelular 4 de csf-1r
PE20120582A1 (es) Conjugados de insulina cristalina
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
AR060188A1 (es) Procedimiento de conjugacion
CL2011002369A1 (es) Una composicion inmunogenica que comprende: un sacarido capsular neumococico conjugado, incluyendo sacarido depolimerizado de serotipo 18c; y antigeno de proteina de union a factor h (fhbp) meningococico, pero sin incluir vesiculas de membrana meningococida. y metodo de preparacion de la composicion.
AR059423A1 (es) Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure